Peptide Therapy · MOTS-c & Elamipretide

MOTS-c vs Elamipretide: What Mitochondrial Medicine Can—and Cannot—Claim

An evidence-first comparison of MOTS-c and elamipretide (SS-31): mechanisms, human trial results, the Barth syndrome accelerated approval, and what remains unproven.

Medical reviewer: Dr. Kish Carlton, MD · Mind Body Spirit Medicine · Last reviewed · 8 min read

Cross-section illustration of a mitochondrion showing the outer membrane, folded inner-membrane cristae, matrix, and electron transport chain complexes, with cardiolipin phospholipids highlighted in the inner membrane.

Watch the episode

Mitochondrial medicine is entering a more precise era. Instead of treating mitochondria as simple batteries, researchers increasingly study them as dynamic signaling networks that influence metabolism, oxidative stress, inflammation, cellular survival, and communication with the nucleus.

Two peptides illustrate how different those strategies can be: MOTS-c and elamipretide, formerly known as SS-31.

The comparison is scientifically exciting. It is also easy to overstate. Laboratory mechanisms, animal recovery, human biomarkers, randomized clinical outcomes, and regulatory approval represent different levels of evidence.

Two different mitochondrial strategies

MOTS-c was identified as a 16-amino-acid peptide associated with a short open reading frame in mitochondrial genetic material. Under laboratory conditions, metabolic stress can cause MOTS-c to move toward the nucleus and influence stress-response genes. This has led to a useful explanatory model: MOTS-c may function as a mitochondrial stress messenger that helps coordinate metabolic adaptation.

Elamipretide is different. It is a synthetic tetrapeptide that binds cardiolipin, a specialized phospholipid in the inner mitochondrial membrane. Cardiolipin helps organize cristae and supports protein systems involved in electron transport and cellular bioenergetics. Elamipretide is therefore better understood as a membrane- and cristae-focused intervention.

These are conceptual models, not exclusive or complete mechanisms. The compounds are not interchangeable simply because both are discussed as mitochondrial peptides.

What the MOTS-c evidence shows

Cell and animal studies have reported effects involving energy-sensing pathways, antioxidant responses, insulin sensitivity, skeletal-muscle adaptation, and age-associated physical decline. Human studies have measured endogenous MOTS-c during exercise or examined correlations with muscle and metabolic features.

Those human findings are biomarker or physiology evidence. They do not prove that administering MOTS-c improves metabolism, athletic performance, recovery, health span, or longevity. No established therapeutic human outcome or Food and Drug Administration-approved MOTS-c indication was identified for this review.

Elamipretide’s important regulatory milestone

On September 19, 2025, the United States Food and Drug Administration granted accelerated approval to elamipretide, marketed as Forzinity, to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kilograms.

This was a meaningful milestone for a rare mitochondrial disease. The label states that approval was based on improvement in knee-extensor muscle strength, an intermediate clinical endpoint, and that continued approval may depend on confirmatory evidence.

The indication is narrow. It is not an approval for aging, fatigue generally, metabolic optimization, heart failure, myocardial-infarction recovery, or general mitochondrial enhancement.

Mixed and negative human results matter

In the phase 3 MMPOWER-3 trial, 218 people with primary mitochondrial myopathy were randomized to elamipretide or placebo for 24 weeks. Elamipretide did not improve six-minute walk distance or total fatigue compared with placebo.

This is an important lesson in translational science: a plausible mechanism and favorable preclinical findings do not guarantee a meaningful clinical outcome.

What about recovery after a heart attack?

Myocardial infarction interrupts blood flow to heart muscle. Restoring circulation is lifesaving, but reperfusion can produce additional mitochondrial and oxidative injury.

In laboratory and animal work, MOTS-c has been linked to membrane repair and reduced ischemia-reperfusion injury. Elamipretide has improved mitochondrial respiration and reduced cristae fragmentation in rat-heart experiments. Other preclinical work has reported less adverse remodeling and better ventricular function after experimental infarction.

These findings are preclinical.

In the randomized EMBRACE STEMI human trial, elamipretide was administered around the time blood flow was restored in people experiencing a first anterior ST-elevation myocardial infarction. The treatment did not reduce infarct size compared with placebo.

It is therefore inaccurate to say either peptide repairs the human heart after a heart attack.

What would need to be proven?

An intervention described as improving health span should demonstrate meaningful human outcomes such as preserved strength, mobility, cognition, metabolic health, resilience after illness, or reduced disability over an appropriate period.

A cardiac-recovery claim would require evidence of improved ventricular function, fewer heart-failure events, better quality of life, fewer hospitalizations, or improved survival in patients—not only favorable cell or animal findings.

MOTS-c has not crossed those thresholds. Elamipretide has crossed a narrower regulatory threshold in Barth syndrome under accelerated approval, but not the broad threshold implied by anti-aging or cardiac-repair marketing.

The evidence-first conclusion

MOTS-c represents the mitochondrial stress-messenger story. Elamipretide represents the mitochondrial membrane story.

Together, they provide genuine reasons for optimism about the future of mitochondrial medicine. That optimism remains most useful when possibility, mechanism, preclinical evidence, and demonstrated human benefit stay clearly separated.

Work with Dr. Kish Carlton

If you are interested in working with Dr. Kish Carlton, learn more at www.MindBodySpirit-DPC.com. There is no pressure — it is simply a place to read more and decide whether this practice fits your goals.

References

Medical disclaimer

This article is educational and does not provide individualized medical advice or instructions for obtaining, preparing, dosing, or using peptides.